Trevi Therapeutics Inc.

Company Overview

Business Model: TREVI THERAPEUTICS, INC. is a clinical-stage biopharmaceutical company focused on developing and commercializing Haduvio (oral nalbuphine ER). Haduvio is an oral extended-release formulation of nalbuphine, which acts as a kappa agonist and mu antagonist (KAMA) on the cough reflex arc. The company is primarily targeting chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease (non-IPF ILD), and refractory chronic cough (RCC). Nalbuphine has a history of over 30 years as an injectable for pain and is not scheduled as a controlled substance in the U.S. and most of Europe. TREVI THERAPEUTICS, INC. has retained worldwide commercial rights for Haduvio.

Market Position: The company operates in therapeutic areas with significant unmet needs. There are currently no approved therapies for chronic cough in patients with IPF or non-IPF ILD. For RCC, while some therapies exist (e.g., Gefapixant approved in Japan and E.U.), the U.S. market has seen a withdrawal of an FDA application for a competitor. TREVI THERAPEUTICS, INC. aims to differentiate Haduvio through its unique KAMA mechanism and potential for unscheduled status, as supported by positive Human Abuse Potential (HAP) study results. The competitive landscape includes other biopharmaceutical companies developing treatments for chronic cough, some of which possess greater financial resources.

Recent Strategic Developments:

• Chronic Cough in IPF Program:
  • Announced positive Phase 2 CANAL trial data, demonstrating statistically significant reductions in daytime and 24-hour cough frequency (p<0.0001).
  • Completed enrollment for the Phase 2b CORAL dose-ranging clinical trial in February 2025, with topline results expected in the second quarter of 2025.
  • Ongoing Phase 1b TIDAL study to evaluate Haduvio's effect on respiratory physiology in IPF patients, informing future Phase 3 trials.
  • Plans to request an end of Phase 2 meeting with the FDA in 2025 and initiate a Phase 3 program in the first half of 2026, contingent on CORAL results.
• Refractory Chronic Cough (RCC) Program:
  • Announced positive topline data from the Phase 2a RIVER trial in March 2025, showing a statistically significant 67% reduction in 24-hour cough frequency from baseline (57% placebo-adjusted, p<0.0001).
  • Planning the next clinical trial to determine dose response and select doses for pivotal studies.
• Prurigo Nodularis Program: Development has been paused to prioritize chronic cough indications, despite previously reporting positive Phase 2b/3 PRISM trial results.
• Human Abuse Potential (HAP) Study: Positive topline results announced in December 2024, indicating statistically significantly lower "Drug Liking" for clinical doses of oral nalbuphine compared to IV butorphanol, which will inform scheduling considerations.
• Hepatic Impairment Study: Completed a Phase 1b clinical trial, with data intended to support a New Drug Application (NDA) submission.
• Funding: Issued and sold 12.5 million shares in a December 2024 offering, generating net proceeds of $47.0 million.

Geographic Footprint: The company's principal executive offices are located in New Haven, Connecticut, U.S. Clinical development programs involve sites in the U.S., U.K., Canada, and ten other countries. Commercialization strategy includes a focused, specialty sales force in the U.S. and third-party collaboration, distribution, and marketing arrangements outside the U.S.

Financial Performance

Revenue Analysis

Profitability Metrics:

• Gross Margin: Not applicable
• Operating Margin: Not applicable
• Net Margin: Not applicable

Investment in Growth:

• R&D Expenditure: $39.4 million in 2024, an increase of 66.3% from $23.7 million in 2023. R&D expenditure represented 76.5% of operating expenses in 2024, up from 69.8% in 2023, reflecting increased clinical development activities.
• Capital Expenditures: $0.04 million in 2024, a decrease of 74.5% from $0.14 million in 2023.
• Strategic Investments: Primarily focused on the clinical development of Haduvio across its target indications.

Capital Allocation Strategy

Shareholder Returns:

• Share Repurchases: Not disclosed.
• Dividend Payments: The company has never declared or paid cash dividends and does not intend to do so in the foreseeable future.
• Dividend Yield: Not applicable.
• Future Capital Return Commitments: None.

Balance Sheet Position:

• Cash and Equivalents: $34.1 million as of December 31, 2024.
• Total Debt: $0 as of December 31, 2024, following the full extinguishment of the SVB Term Loan in May 2023.
• Net Cash Position: $107.6 million (comprising cash, cash equivalents, and marketable securities) as of December 31, 2024.
• Credit Rating: Not disclosed.
• Debt Maturity Profile: No outstanding debt as of December 31, 2024.

Cash Flow Generation:

• Operating Cash Flow: $(38.3) million in 2024, an increase in outflow of 20.6% from $(31.7) million in 2023, driven by increased R&D activities.
• Free Cash Flow: Not explicitly stated.
• Cash Conversion Metrics: Not disclosed.
• Funding Outlook: Existing cash, cash equivalents, and marketable securities are expected to fund operating expenses and capital expenditure requirements into the second half of 2026.

Operational Excellence

Production & Service Model: TREVI THERAPEUTICS, INC. operates a virtual manufacturing model, relying entirely on third-party contract manufacturers for the production of nalbuphine hydrochloride drug substance and Haduvio tablets for both clinical trials and planned commercial supply. The company does not own any manufacturing facilities.

Supply Chain Architecture: Key Suppliers & Partners:

• Drug Substance: Mallinckrodt - Serves as the single supplier for nalbuphine hydrochloride drug substance.
• Manufacturing Partners: Third-party contract manufacturers - Responsible for Haduvio tablet manufacturing, storage, packaging, and distribution. The company currently does not have long-term supply agreements with these manufacturers.

Facility Network:

• Headquarters: The company leases 12,500 square feet of office space in New Haven, Connecticut, U.S., with the lease expiring in February 2028 and an option for a five-year extension.
• Manufacturing, Research & Development, and Distribution: These functions are outsourced to third-party facilities.

Operational Metrics: Operational metrics such as capacity utilization or specific efficiency measures are not explicitly disclosed in the filing.

Market Access & Customer Relationships

Go-to-Market Strategy: Distribution Channels:

• Direct Sales (U.S.): For the U.S. market, the company plans to establish its own focused, specialty sales force. This team will target pulmonologists and Interstitial Lung Disease (ILD) centers of excellence for IPF and non-IPF ILD indications, and pulmonologists and allergists for the RCC indication.
• Channel Partners (Outside U.S.): For markets outside the U.S., the company intends to leverage collaboration, distribution, and other marketing arrangements with third parties.

Customer Portfolio: As a clinical-stage biopharmaceutical company, TREVI THERAPEUTICS, INC. does not yet have a commercial customer portfolio.

Geographic Revenue Distribution: Not applicable, as the company currently generates no revenue.

Competitive Intelligence

Market Structure & Dynamics

Industry Characteristics: The chronic cough market, particularly for IPF and non-IPF ILD, represents a significant unmet medical need, with no currently approved therapies. IPF affects approximately 140,000 adults in the U.S. and over 1 million worldwide, with up to 85% experiencing chronic cough. Non-IPF ILDs affect a similar number of adults globally, with 60-70% suffering from chronic cough. The RCC market is larger, affecting 2-3 million adults in the U.S., with some approved therapies in other regions (e.g., Gefapixant in Japan and E.U.).

Competitive Positioning Matrix:

Direct Competitors

Primary Competitors:

• IPF/non-IPF ILD Chronic Cough:
  • Nerre Therapeutics (orvepitant)
  • Melius Pharma (ME-015)
  • Boehringer Ingelheim (BI 1839100)
  • Seyltx, Inc. (ifenprodil)
  • No current product candidates are specifically in clinical development for non-IPF ILD chronic cough.
• Refractory Chronic Cough (RCC):
  • GSK plc (camlipixant)
  • Nocion Therapeutics Inc. (taplucainium)
  • Axalbion Therapeutics Ltd. (AX-8)
  • Addex Therapeutics Ltd. (GABAB PAM)
  • Seyltx, Inc. (ifenprodil)
  • Gefapixant (P2X3 antagonist) is approved in Japan and E.U.
• Non-specific cough therapeutics: Includes older, non-specific treatments such as benzonatate, opioids, corticosteroids, proton-pump inhibitors, and neuromodulators.

Emerging Competitive Threats: The company faces ongoing competition from new entrants and the advancement of other product candidates in clinical development for chronic cough.

Competitive Response Strategy: TREVI THERAPEUTICS, INC.'s strategy is to advance Haduvio through clinical development for its target chronic cough indications, particularly those with high unmet needs. The company aims to leverage Haduvio's distinct mechanism of action and potential for a favorable regulatory classification (unscheduled status) to establish a competitive advantage.

Risk Assessment Framework

Strategic & Market Risks

Market Dynamics:

• Competition: The company faces competition from other biopharmaceutical companies, many of which have greater financial resources and development expertise.
• Technology Disruption: Risk of new, more effective, or safer treatments emerging from competitors or new technologies.

Operational & Execution Risks

Supply Chain Vulnerabilities:

• Supplier Dependency: The company relies on a single supplier, Mallinckrodt, for its nalbuphine hydrochloride drug substance, creating a concentration risk.
• Manufacturing Dependency: Reliance on third-party contract manufacturers for Haduvio tablet production, storage, packaging, and distribution, without long-term supply agreements, poses risks related to supply continuity and scalability.
• Capacity Constraints: Potential for manufacturing delays or insufficient capacity to meet future commercial demand.

Financial & Regulatory Risks

Market & Financial Risks:

• Credit & Liquidity: The company is dependent on its existing cash, cash equivalents, and marketable securities, which are projected to fund operations into the second half of 2026. Future funding will be required to complete clinical development and commercialization.
• Regulatory Approval: Haduvio is subject to extensive U.S. and international regulatory requirements, and there is no guarantee of obtaining marketing approval.
• Drug Scheduling: Despite positive HAP study results, the U.S. DEA could still classify Haduvio as a controlled substance (Schedule V or IV), which could impact commercialization.
• Opioid Class Label Warning: If approved, Haduvio is likely to carry an opioid class label warning for serious respiratory depression, which could affect its market adoption.

Regulatory & Compliance Risks:

• Industry Regulation: Subject to a complex and evolving regulatory landscape, including the FDCA, HIPAA, GDPR, FCPA, ACA, IRA, cGMP, cGCP, PREA, CTR, and HTA.
• Drug Pricing Legislation: The U.S. Inflation Reduction Act (IRA) could significantly impact future drug pricing and profitability, with price negotiations for certain drugs commencing in 2026.
• International Regulatory Changes: Changes in E.U. pharmaceutical legislation could reduce regulatory data protection duration, and new regulations like the E.U. Clinical Trials Regulation (CTR) and the UK's International Recognition Procedure (IRP) add complexity.
• Data Privacy: Compliance with stringent data privacy laws such as GDPR, CCPA, CPRA, and Washington state's My Health My Data Act, with potential for substantial fines for violations.

Geopolitical & External Risks

Geopolitical Exposure:

• Geographic Dependencies: Clinical trials conducted across multiple countries expose the company to diverse regulatory, political, and economic environments.
• Sanctions & Export Controls: Compliance with international sanctions and export control regulations may limit business activities in certain regions.

Innovation & Technology Leadership

Research & Development Focus: Core Technology Areas:

• Kappa Agonist and Mu Antagonist (KAMA): Haduvio's mechanism of action, targeting the cough reflex arc, represents a novel approach to chronic cough treatment.
• Extended-Release Formulation: Development of an oral extended-release formulation of nalbuphine to optimize dosing and patient convenience.
• Innovation Pipeline: The primary focus is on advancing Haduvio through clinical development for chronic cough in IPF, non-IPF ILD, and RCC, with ongoing studies to further characterize its efficacy, safety, and physiological effects.

Intellectual Property Portfolio:

• Patent Strategy: The company owns five U.S. patents, 19 foreign patents, and multiple pending U.S. and foreign patent applications related to methods of use for Haduvio. This includes a U.S. patent covering the use of Haduvio for chronic cough in IPF, and a recently allowed U.S. patent application for its use in IPF patients with hepatic impairment. Issued patents expire between 2032 and 2039, with potential extensions for pending applications up to 2045.
• Licensing Programs: TREVI THERAPEUTICS, INC. holds an exclusive, worldwide, sublicensable license from Endo Pharmaceuticals Inc. for nalbuphine hydrochloride products, covering Haduvio's formulation (patents expire 2026-2029). The agreement includes milestone payments to Endo Pharmaceuticals Inc. upon Phase 3 completion ($0.3 million) and U.S. marketing approval ($0.8 million), plus royalties on net sales. The company does not own or exclusively license any composition of matter patents for Haduvio.
• IP Litigation: No material IP litigation is disclosed.

Technology Partnerships:

• Strategic Alliances: The licensing agreement with Endo Pharmaceuticals Inc. represents a key strategic alliance for Haduvio's formulation.
• Research Collaborations: Not explicitly detailed beyond the conduct of clinical trials at various sites.

Leadership & Governance

Executive Leadership Team

The filing does not provide a comprehensive list of executive officers with their tenure and prior experience in the requested format. However, it notes that the Chief Information Officer (a part-time consultant with over 25 years of IT experience, a bachelor's in Technology, an MBA, and over 10 years of life sciences IT experience) leads a quarterly cybersecurity committee, which also includes the Chief Executive Officer and Chief Financial Officer.

Leadership Continuity: Not explicitly detailed in the filing.

Board Composition: The Audit Committee of the Board of Directors provides direct oversight over cybersecurity risk, receiving periodic updates from management.

Human Capital Strategy

Workforce Composition:

• Total Employees: As of December 31, 2024, the company had 26 employees.
• Geographic Distribution: Not explicitly detailed, but headquarters are in New Haven, Connecticut.
• Skill Mix: The workforce comprises 16 employees in Research & Development and 10 in general management and administration. None of the employees are represented by labor unions.

Talent Management: Acquisition & Retention:

• Hiring Strategy: The company's objectives include identifying, recruiting, retaining, incentivizing, and integrating employees.
• Retention Metrics: Specific retention metrics are not disclosed.
• Employee Value Proposition: The company benchmarks its total rewards package, including compensation, 401(k) plans, benefits, and paid time off, against industry peers to attract and retain talent.

Diversity & Development:

• Diversity Metrics: Specific diversity metrics are not disclosed.
• Development Programs: All employees annually receive data protection and cybersecurity training.
• Culture & Engagement: Not explicitly detailed.

Regulatory Environment & Compliance

Regulatory Framework: Industry-Specific Regulations:

• Drug Development & Approval: Haduvio's development and potential approval are subject to extensive regulations from the U.S. FDA (intending to pursue a Section 505(b)(2) pathway), E.U. health authorities (under the E.U. Clinical Trials Regulation (CTR) and ongoing pharmaceutical legislation review), and the UK's MHRA (under the new International Recognition Procedure (IRP)).
• Healthcare Laws: Compliance is required with various U.S. and international healthcare laws, including the Federal Food, Drug, and Cosmetic Act (FDCA), Health Insurance Portability and Accountability Act (HIPAA), Foreign Corrupt Practices Act (FCPA), Affordable Care Act (ACA), Inflation Reduction Act (IRA), current Good Manufacturing Practices (cGMP), current Good Clinical Practices (cGCP), Pediatric Research Equity Act (PREA), and Health Technology Assessment (HTA) requirements.
• Data Privacy: The company must comply with stringent data privacy regulations such as the E.U.'s General Data Protection Regulation (GDPR), California Consumer Privacy Act (CCPA), California Privacy Rights Act (CPRA), and Washington state's My Health My Data Act.
• Drug Pricing: The U.S. Inflation Reduction Act (IRA), enacted in August 2022, will impact Medicare Part D and requires price negotiations for certain drugs starting in 2026, potentially affecting future revenue and profitability.
• Drug Importation: The FDA's approval of Florida's plan for Canadian drug importation (January 5, 2024) could introduce new market dynamics.

Trade & Export Controls:

• Export Restrictions: The company is subject to various trade restrictions and export controls, requiring compliance with licensing requirements and country-specific limitations.
• Sanctions Compliance: Compliance monitoring is necessary to avoid transactions with sanctioned entities.

Legal Proceedings: The company is not currently subject to any material legal proceedings.

Tax Strategy & Considerations

Tax Profile:

• Effective Tax Rate: The company reported an effective tax rate of 0.1% for both 2024 and 2023.
• Geographic Tax Planning: Not explicitly detailed beyond federal and state tax considerations.
• Tax Reform Impact:
  • Section 174 of TCJA: Beginning in 2022, the Tax Cuts and Jobs Act (TCJA) requires the capitalization and amortization of Research & Development (R&D) expenditures over five years for U.S. activities and 15 years for non-U.S. activities. This resulted in additional deferred tax assets of $7.6 million in 2024 and $4.8 million in 2023.
• Net Operating Loss (NOL) Carryforwards: As of December 31, 2024, the company had $199.8 million in federal and state NOL carryforwards. Federal NOLs prior to 2018 expire between 2031 and 2037, while those from 2018 onwards carry forward indefinitely but can only offset 80% of taxable income. State NOLs expire between 2031 and 2044. These NOLs are subject to limitations under Section 382 due to historical ownership changes.
• R&D Tax Credit Carryforwards: The company held $7.3 million in federal R&D tax credit carryforwards (expiring 2032-2044) and $244 in state R&D tax credit carryforwards as of December 31, 2024.
• Accumulated Deficit: As of December 31, 2024, the company had an accumulated deficit of $287.0 million.
• Valuation Allowance: A valuation allowance of $82.4 million was recorded against net deferred tax assets in 2024, up from $69.5 million in 2023.

Insurance & Risk Transfer

Risk Management Framework:

• Insurance Coverage: TREVI THERAPEUTICS, INC. maintains product and clinical trial liability insurance with aggregate coverage of at least $10.0 million.
• Risk Transfer Mechanisms: The company does not maintain environmental liability or toxic tort claims insurance.